Phosphodiesterase 5 inhibitors in vascular systemic disorders

被引：4
|
作者：
Allanore, Yannick [1 ]
机构：
[1] Univ Paris 05, INSERM U1016, Serv Rhumatol, Hop Cochin, F-75014 Paris, France
来源：
JOINT BONE SPINE | 2012年 / 79卷 / 04期
关键词：
Phosphodiesterase; Nitric oxide; Pulmonary hypertension; Raynaud's phenomenon; Sildenafil; Tadalafil; PULMONARY ARTERIAL-HYPERTENSION; RAYNAUDS-PHENOMENON RESISTANT; DOUBLE-BLIND; SILDENAFIL; THERAPY; TADALAFIL; SCLEROSIS; EFFICACY;
D O I：
10.1016/j.jbspin.2011.12.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：338 / 340
页数：3
相关论文
共 50 条
  • [1] Phosphodiesterase Type 5 Inhibitors in Pulmonary Arterial Hypertension
    Montani, David
    Chaumais, Marie-Camille
    Savale, Laurent
    Natali, Delphine
    Price, Laura C.
    Jais, Xavier
    Humbert, Marc
    Simonneau, Gerald
    Sitbon, Olivier
    ADVANCES IN THERAPY, 2009, 26 (09) : 813 - 825
  • [2] Predictors of the response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension: an analysis of the Spanish registry
    Garcia, Agustin R.
    Blanco, Isabel
    Ramon, Lluis
    Perez-Sagredo, Jesus
    Guerra-Ramos, Francisco J.
    Martin-Ontiyuelo, Clara
    Tura-Ceide, Olga
    Pastor-Perez, Francisco
    Escribano-Subias, Pilar
    Barbera, Joan A.
    RESPIRATORY RESEARCH, 2023, 24 (01)
  • [3] Phosphodiesterase 5 inhibitors: are they cardioprotective?
    Reffelmann, Thorsten
    Kloner, Robert A.
    CARDIOVASCULAR RESEARCH, 2009, 83 (02) : 204 - 212
  • [4] Polypharmacological Potential of Phosphodiesterase 5 Inhibitors for the Treatment of Neurocognitive Disorders
    Kumar, Ashish
    Kim, Fred
    Song, Dong-Keun
    Choung, Jai Jun
    AGING AND DISEASE, 2024, 15 (05): : 2008 - 2014
  • [5] Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children
    Magee, Alan G.
    Makhecha, Sukeshi
    Bentley, Sian
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (05) : 633 - 642
  • [6] Phosphodiesterase-5 (PDE-5) Inhibitors and Ototoxicity: A Systematic Review
    Manna, Sayan
    Gray, Mingyang Liu
    Kaul, Vivian F.
    Wanna, George
    OTOLOGY & NEUROTOLOGY, 2019, 40 (03) : 276 - 283
  • [7] Effects of phosphodiesterase type 5 inhibitors on Raynaud's phenomenon
    Kamata, Yasuyuki
    Minota, Seiji
    RHEUMATOLOGY INTERNATIONAL, 2014, 34 (11) : 1623 - 1626
  • [8] Recreational use and misuse of phosphodiesterase 5 inhibitors
    Smith, KM
    Romanelli, F
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2005, 45 (01) : 63 - 75
  • [9] Phosphodiesterase 5 inhibitors in male sexual dysfunction
    Kuthe, A
    CURRENT OPINION IN UROLOGY, 2003, 13 (05) : 405 - 410
  • [10] Phosphodiesterase type 5 inhibitors for erectile dysfunction
    Carson, CC
    Lue, TF
    BJU INTERNATIONAL, 2005, 96 (03) : 257 - 280
12345